%0 Journal Article
%A Heitmann, Jonas
%A Tandler, Claudia
%A Marconato, Maddalena
%A Nelde, Annika
%A Habibzada, Timorshah
%A Rittig, Susanne M
%A Tegeler, Christian M
%A Maringer, Yacine
%A Jaeger, Simon U
%A Denk, Monika
%A Richter, Marion
%A Oezbek, Melek T
%A Wiesmüller, Karl-Heinz
%A Bauer, Jens
%A Rieth, Jonas
%A Wacker, Marcel
%A Schroeder, Sarah M
%A Hoenisch Gravel, Naomi
%A Scheid, Jonas
%A Märklin, Melanie
%A Henrich, Annika
%A Klimovich, Boris
%A Clar, Kim L
%A Lutz, Martina Svenja
%A Holzmayer, Samuel
%A Hörber, Sebastian
%A Peter, Andreas
%A Meisner, Christoph
%A Fischer, Imma
%A Löffler, Markus W
%A Peuker, Caroline Anna
%A Habringer, Stefan
%A Goetze, Thorsten O
%A Jäger, Elke
%A Rammensee, Hans-Georg
%A Salih, Helmut
%A Walz, Juliane
%T Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency.
%J Nature Communications
%V 14
%N 1
%@ 2041-1723
%C [London]
%I Nature Publishing Group UK
%M DKFZ-2023-01685
%P 5032
%D 2023
%X T-cell immunity is central for control of COVID-19, particularly in patients incapable of mounting antibody responses. CoVac-1 is a peptide-based T-cell activator composed of SARS-CoV-2 epitopes with documented favorable safety profile and efficacy in terms of SARS-CoV-2-specific T-cell response. We here report a Phase I/II open-label trial (NCT04954469) in 54 patients with congenital or acquired B-cell deficiency receiving one subcutaneous CoVac-1 dose. Immunogenicity in terms of CoVac-1-induced T-cell responses and safety are the primary and secondary endpoints, respectively. No serious or grade 4 CoVac-1-related adverse events have been observed. Expected local granuloma formation has been observed in 94
%K Humans
%K COVID-19
%K SARS-CoV-2
%K T-Lymphocytes
%K Agammaglobulinemia
%K Peptides: therapeutic use
%K COVAC-1 COVID-19 vaccine (NLM Chemicals)
%K Peptides (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:37596280
%2 pmc:PMC10439231
%R 10.1038/s41467-023-40758-0
%U https://inrepo02.dkfz.de/record/278641